Assessing the Adverse Events of Roflumilast and Tapinarof Use in Pediatric and Young Adult Patients with Atopic Dermatitis: A Systematic Review.
Anya Ramsamooj, Bethany M Joy, Dave D Manguerra et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review evaluated the adverse events associated with roflumilast and tapinarof in pediatric and young adult patients with atopic dermatitis. Analyzing data from seven studies involving 3615 patients, the review found that both treatments significantly increased the risk of treatment-emergent adverse events compared to vehicle controls, with roflumilast showing a risk ratio of 1.46 and tapinarof 1.49.
Key findings
- Roflumilast was associated with a risk ratio of 1.46 for treatment-emergent adverse events compared to vehicle control.
- Tapinarof showed a risk ratio of 1.49 for treatment-emergent adverse events compared to vehicle control.
- Roflumilast had a significantly increased risk of treatment-related adverse events (RR = 1.92).
- Tapinarof was associated with dermatologic adverse events, while roflumilast was linked to nondermatologic events.
Why it matters
Understanding the distinct adverse event profiles of roflumilast and tapinarof is crucial for clinicians when selecting treatments for atopic dermatitis in pediatric populations. This knowledge aids in individualizing therapy and monitoring for potential adverse effects.